HUTCHMED Ltd

HUTCHMED Ltd is the next name that is known as the leading biotech company in Hong Kong. It was formerly called Hutchison China MediTech Limited and changed its name to HUTCHMED Ltd in May 2021. It is one of the first global-focused novel drug discovery companies in China. The company was incorporated in 2000 and its headquarter is in Central, Hong Kong.

HUTCHMED is among the first global-focused novel drug discovery companies in China. It is divided into two reported segments including oncology, immunology, and other ventures. Over the past two decades, this company has established a completely integrated R&D platform with world-class discovery and development capabilities. Since its establishment, it has built up 13 cancer drug candidates from internal discovery into clinical studies across the globe, with the first three oncology drugs currently accepted and marketed.

HUTCHMED is an innovative and commercial-stage biopharmaceutical institution. It constantly discovers, enhances, and commercializes aimed cure and immunotherapies for cancer and immunological diseases in both HongKong and overseas. Thanks to this, over 1,300 staffs have developed ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and launched. This organization also has a portfolio of several cancer drug candidates currently in clinical studies across the globe and extensive commercial infrastructure in its home market.

Founded: 2000

Headquarters: Central, Hong Kong

Website: https://www.hutch-med.com/